A study from the Salk Institute, published in Cell Reports on September 10, 2026, is the first to show that B cells can regulate the function of killer T cells - the immune cells that do the actual work of destroying tumor cells. The research, led by Daniel Hollern, PhD, found that B cells play a multifaceted role in promoting T cell anti-tumor activity rather than serving as passive bystanders in the immune response.
That matters because most current immunotherapy is built around T cells. These treatments work by boosting the performance of the adaptive immune system's T cells, and they have reshaped cancer care for many patients. But not everyone responds, and the reasons why remain incompletely understood. If B cells help set the terms under which killer T cells operate, they represent a second lever that clinicians and drug developers have barely touched.
B cells have remained comparatively understudied in tumor immunology, which Hollern's lab describes as a research gap that has kept them from reaching their clinical potential. Identifying a direct regulatory relationship is a starting point, not an endpoint - the finding raises a set of new questions about exactly how these cell-to-cell interactions work and under what conditions they help.
Cancer remains the second leading cause of death in the United States, according to a 2026 Cancer Research Institute report, and the practical payoff here depends on whether the biology can be translated into something that extends the benefit of immunotherapy to patients who currently see none.